Long-term outcome and sequelae in aggressive lymphoma patients treated with the LNH-80 regimen.

Abstract

One hundred patients with aggressive malignant lymphoma treated with the LNH-80 regimen were evaluated for long-term survival, late relapse and long-term sequelae. The LNH-80 regimen consisted of three intensive courses of adriamycin, cyclophosphamide, vindesine and bleomycin, followed by consolidation and final intensification, as previously described. Of the eighty-four patients who achieved CR after induction, fifty-two are alive in continuous complete remission with a median follow-up of 9.2 years. Twenty-nine CR patients (35%) relapsed. Sixty-six percent of the relapses occurred during the first 18 months following the end of treatment but late relapses were observed up to 7 years off-therapy. The fifty-two long-term responders were evaluated for their ability to resume work, sexual function, fertility and presence of long-term sequelae. Of the 41 patients who worked before diagnosis of their disease, 66% had resumed their normal jobs and 24% had retired. Sexual activity was considered to be satisfactory by 66% of the patients. Eleven of the 15 patients (73%) who wanted children had between one and three children. Seven patients (14%) were considered to have mild long-term sequelae but all long-term survivors reported having an acceptable quality of life. Five of the patients who reached CR (6%) had second neoplasias. The LNH-80 regimen allowed 52% of the patients to benefit from long-term disease-free survival with minor long-term toxicity.

• Authors: C Dumontet, Y Bastion, P Felman, M Ffrench, M Blanc, P Y Peaud, B Coiffier
• Journal: Annals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 3 Issue 8 Pg. 639-44 (Sep 1992) ISSN: 0923-7534 [Print] England
• PMID: 1280459 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Bleomycin
• Doxorubicin
• Cyclophosphamide
• Vindesine

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bleomycin (administration & dosage)
• Child
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Female
• Humans
• Lymphoma (drug therapy, mortality)
• Male
• Middle Aged
• Survival Rate
• Treatment Outcome
• Vindesine (administration & dosage)